Journal of Clinical and Translational Hepatology

Papers
(The H4-Index of Journal of Clinical and Translational Hepatology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies271
Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease185
Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options46
Liver Transplantation Beyond Milan Criteria45
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver44
NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States35
Incidence, Mortality and Predictors of Acute Kidney Injury in Patients with Cirrhosis: A Systematic Review and Meta-analysis30
Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review30
Macrophage Phenotypes and Hepatitis B Virus Infection29
Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease29
Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases28
What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective27
Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study26
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD23
Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?20
Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications20
Liver Dysfunction and Its Association with the Risk of Death in COVID-19 Patients: A Prospective Cohort Study19
Acute Hepatitis of Unknown Origin in Children: Early Observations from the 2022 Outbreak19
Antihepatic Fibrosis Drugs in Clinical Trials18
0.035017013549805